Medpace Holdings Inc
NASDAQ:MEDP

Watchlist Manager
Medpace Holdings Inc Logo
Medpace Holdings Inc
NASDAQ:MEDP
Watchlist
Price: 337.75 USD -1.19% Market Closed
Market Cap: 10.5B USD
Have any thoughts about
Medpace Holdings Inc?
Write Note

Intrinsic Value

The intrinsic value of one MEDP stock under the Base Case scenario is 286.45 USD. Compared to the current market price of 337.75 USD, Medpace Holdings Inc is Overvalued by 15%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

MEDP Intrinsic Value
286.45 USD
Overvaluation 15%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Medpace Holdings Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for MEDP cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about MEDP?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Medpace Holdings Inc

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Medpace Holdings Inc

Provide an overview of the primary business activities
of Medpace Holdings Inc.

What unique competitive advantages
does Medpace Holdings Inc hold over its rivals?

What risks and challenges
does Medpace Holdings Inc face in the near future?

Has there been any significant insider trading activity
in Medpace Holdings Inc recently?

Summarize the latest earnings call
of Medpace Holdings Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Medpace Holdings Inc.

Provide P/S
for Medpace Holdings Inc.

Provide P/E
for Medpace Holdings Inc.

Provide P/OCF
for Medpace Holdings Inc.

Provide P/FCFE
for Medpace Holdings Inc.

Provide P/B
for Medpace Holdings Inc.

Provide EV/S
for Medpace Holdings Inc.

Provide EV/GP
for Medpace Holdings Inc.

Provide EV/EBITDA
for Medpace Holdings Inc.

Provide EV/EBIT
for Medpace Holdings Inc.

Provide EV/OCF
for Medpace Holdings Inc.

Provide EV/FCFF
for Medpace Holdings Inc.

Provide EV/IC
for Medpace Holdings Inc.

Show me price targets
for Medpace Holdings Inc made by professional analysts.

What are the Revenue projections
for Medpace Holdings Inc?

How accurate were the past Revenue estimates
for Medpace Holdings Inc?

What are the Net Income projections
for Medpace Holdings Inc?

How accurate were the past Net Income estimates
for Medpace Holdings Inc?

What are the EPS projections
for Medpace Holdings Inc?

How accurate were the past EPS estimates
for Medpace Holdings Inc?

What are the EBIT projections
for Medpace Holdings Inc?

How accurate were the past EBIT estimates
for Medpace Holdings Inc?

Compare the revenue forecasts
for Medpace Holdings Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Medpace Holdings Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Medpace Holdings Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Medpace Holdings Inc compared to its peers.

Compare the P/E ratios
of Medpace Holdings Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Medpace Holdings Inc with its peers.

Analyze the financial leverage
of Medpace Holdings Inc compared to its main competitors.

Show all profitability ratios
for Medpace Holdings Inc.

Provide ROE
for Medpace Holdings Inc.

Provide ROA
for Medpace Holdings Inc.

Provide ROIC
for Medpace Holdings Inc.

Provide ROCE
for Medpace Holdings Inc.

Provide Gross Margin
for Medpace Holdings Inc.

Provide Operating Margin
for Medpace Holdings Inc.

Provide Net Margin
for Medpace Holdings Inc.

Provide FCF Margin
for Medpace Holdings Inc.

Show all solvency ratios
for Medpace Holdings Inc.

Provide D/E Ratio
for Medpace Holdings Inc.

Provide D/A Ratio
for Medpace Holdings Inc.

Provide Interest Coverage Ratio
for Medpace Holdings Inc.

Provide Altman Z-Score Ratio
for Medpace Holdings Inc.

Provide Quick Ratio
for Medpace Holdings Inc.

Provide Current Ratio
for Medpace Holdings Inc.

Provide Cash Ratio
for Medpace Holdings Inc.

What is the historical Revenue growth
over the last 5 years for Medpace Holdings Inc?

What is the historical Net Income growth
over the last 5 years for Medpace Holdings Inc?

What is the current Free Cash Flow
of Medpace Holdings Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Medpace Holdings Inc.

Business Breakdown

Medpace Holdings Inc., a prominent player in the global clinical research organization (CRO) space, has made a name for itself by offering comprehensive drug development services tailored to the needs of pharmaceutical and biotechnology companies. Founded in 1992 and headquartered in Cincinnati, Ohio, the company specializes in conducting clinical trials for innovative therapies across various therapeutic areas, including oncology, cardiology, and infectious diseases. With its unique approach to clinical development, Medpace combines deep operational expertise with a commitment to collaboration and transparency, helping clients navigate the complexities of bringing new drugs to market. The c...

Read More
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Medpace Holdings Inc

Current Assets 1B
Cash & Short-Term Investments 656.9m
Receivables 311.5m
Other Current Assets 64.2m
Non-Current Assets 1.1B
PP&E 254.6m
Intangibles 697.1m
Other Non-Current Assets 99.7m
Current Liabilities 1B
Accounts Payable 26.2m
Accrued Liabilities 330.5m
Other Current Liabilities 684.7m
Non-Current Liabilities 161.3m
Other Non-Current Liabilities 161.3m
Efficiency

Earnings Waterfall
Medpace Holdings Inc

Revenue
2.1B USD
Cost of Revenue
-1.5B USD
Gross Profit
614.8m USD
Operating Expenses
-206m USD
Operating Income
408.8m USD
Other Expenses
-43.2m USD
Net Income
365.6m USD

Free Cash Flow Analysis
Medpace Holdings Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In Q3 2024, the company reported revenues of $533.3 million, an 8.3% increase year-over-year, with a year-to-date total of $1.57 billion, up 13.3%. However, net new business awards fell 12.7%, leading to a book-to-bill ratio of 1.0. The company has a backlog of approximately $2.9 billion, projected to generate $1.62 billion in revenue over the next year. Full year revenue guidance is adjusted to $2.09-2.13 billion, reflecting 10.8-12.9% growth. EBITDA is anticipated between $450-470 million, a 24.1-29.7% increase from last year. Elevated cancellations, especially from projects initiated during the COVID funding surge, remain a significant concern.

What is Earnings Call?
Fundamental Scores

MEDP Profitability Score
Profitability Due Diligence

Medpace Holdings Inc's profitability score is 74/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Positive Free Cash Flow
Exceptional ROE
ROE is Increasing
74/100
Profitability
Score

Medpace Holdings Inc's profitability score is 74/100. The higher the profitability score, the more profitable the company is.

MEDP Solvency Score
Solvency Due Diligence

Medpace Holdings Inc's solvency score is 68/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Low D/E
Long-Term Solvency
Short-Term Solvency
68/100
Solvency
Score

Medpace Holdings Inc's solvency score is 68/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MEDP Price Targets Summary
Medpace Holdings Inc

Wall Street analysts forecast MEDP stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MEDP is 362.35 USD with a low forecast of 308.05 USD and a high forecast of 424.2 USD.

Lowest
Price Target
308.05 USD
9% Downside
Average
Price Target
362.35 USD
7% Upside
Highest
Price Target
424.2 USD
26% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for MEDP?

Click here to dive deeper.

Dividends

Medpace Holdings Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for MEDP is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

MEDP Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

MEDP News

Other Videos

Profile

Medpace Holdings Inc Logo
Medpace Holdings Inc

Country

United States of America

Industry

Life Sciences Tools & Services

Market Cap

10.5B USD

Dividend Yield

0%

Description

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The company is headquartered in Cincinnati, Ohio and currently employs 4,500 full-time employees. The company went IPO on 2016-08-11. The firm is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The firm partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The firm's drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.

Contact

OHIO
Cincinnati
5375 Medpace Way
+15135799911.0
investor.medpace.com

IPO

2016-08-11

Employees

4 500

Officers

Chairman & CEO
Dr. August James Troendle M.D.
President
Mr. Jesse J. Geiger BBA, CPA
CFO & Treasurer
Mr. Kevin M. Brady
Executive Vice President of Operations
Ms. Susan E. Burwig BSN, MA
Chief Compliance Officer, General Counsel & Corporate Secretary
Mr. Stephen P. Ewald J.D.
Chief Information Officer
Brandon Ebken
Show More
Associate Director of Investors Relations
Ms. Lauren Morris
Vice President of Business Development & Marketing
Mr. Todd Meyers
Senior Vice President of Commercial Operations & Clinical Pharmacology Unit
John T. Wynne MBA
Chief Medical Officer of Medical Department
Mr. Reinilde Heyrman M.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one MEDP stock?

The intrinsic value of one MEDP stock under the Base Case scenario is 286.45 USD.

Is MEDP stock undervalued or overvalued?

Compared to the current market price of 337.75 USD, Medpace Holdings Inc is Overvalued by 15%.

Back to Top